Open-label pilot study of quetiapine treatment for cannabis dependence

American Journal of Drug and Alcohol Abuse

Volumn 40, Issue 4, 2014, Pages 280-284

  Mariani, John J ^a,b   Pavlicova, Martina ^c   Mamczur, Agnieszka K ^a   Bisaga, Adam ^a,b   Nunes, Edward V ^a,b   Levin, Frances R ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c Howard Hughes Medical Institute   (United States)

Author keywords

Cannabis; Dependence; Pharmacotherapy; Quetiapine; Treatment

Indexed keywords

CREATININE; GLUCOSE; QUETIAPINE; TETRAHYDROCANNABINOLIC ACID; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; APPETITE; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CONSTIPATION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; FATIGUE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MAXIMUM TOLERATED DOSE; MORNING DOSAGE; OPEN STUDY; PILOT STUDY; SOMNOLENCE; TREATMENT DURATION; WEIGHT GAIN; XEROSTOMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MARIJUANA ABUSE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; PILOT PROJECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903443973     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2014.884102     Document Type: Article

References (33)

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, Publication No. SMA 11-4658; Rockville, MD: Office of Applied Studies, 2011.
2. Stinson FS, Grant BF, Dawson DA, Ruan WJ, Huang B, Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2005;80:105-116.
3. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: Prevalence, correlates and co-morbidity. Psychol Med 2006;36:1447-1460.
4. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000;68:1051-1061.
5. Budney AJ, Moore BA, Rocha HL, Higgins ST. Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 2006;74:307-316.
6. Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, Liddle H, et al. The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials. J Subst Abuse Treat 2004;27:197-213.
7. Group TMTPR. Brief treatments for cannabis dependence: Findings from a randomized multisite trial. J Consult Clin Psychol 2004;72: 455-466.
8. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav 2007;32:1220-1236.
9. Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, Vosburg SK. Pharmacotherapy for marijuana dependence: A double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004;13:21-32.
10. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009;18:53-64.
11. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009;105:132-138.
12. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011;116:142-150.
13. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-Acetylcysteine in cannabisdependent adolescents. Am J Psychiatry 2012;169:805-812.
14. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, et al. A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012;37:1689-1698.
15. Elsohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 2005;78: 539-548.
16. Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: Results from NESARC. J Clin Psychiatry 2008;69:1354-1363.
17. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 2002;63:5-11.
18. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-884.
19. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991-2001.
20. Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: Results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol 2007;21:392-399.
21. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0): Biometrics Research Department, New York State Psychiatric Institute, 1995.
22. Litten R, Allen J. Measuring alcohol consumption: Psychosocial and biochemical methods. Totowa, NJ: The Humana Press Inc., 1992.
23. Mariani JJ, Brooks D, Haney M, Levin FR. Quantification and comparison of marijuana smoking practices: Blunts, joints, and pipes. Drug Alcohol Depend 2011;113:249-251.
24. Steinberg K, Roffman R, Carroll K, McRee B, Babor T, Miller M, Kadden R, et al. Brief counseling for marijuana dependence. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2005.
25. Johnson BA, Ait-Daoud N, Roache JD. The COMBINE SAFTEE: A structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field. J Stud Alcohol Suppl 2005; 15:157-167; discussion 140.
26. Smith PL. Splines as a useful and convenient statistical tool. Am Statistician 1979;33:57-62.
27. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25: 161-166.
28. Benaliouad F, Kapur S, Rompre PP. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 2007;32:551-561.
29. Gallo A, Lapointe S, Stip E, Potvin S, Rompre PP. Quetiapine blocks cocaine-induced enhancement of brain stimulation reward. Behav Brain Res 2010;208:163-168.
30. Jasmin L, Narasaiah M, Tien D. Noradrenaline is necessary for the hedonic properties of addictive drugs. Vascular Pharmacol 2006;45: 243-250.
31. Budney AJ, Novy PL, Hughes Jr. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999;94:1311-1322.
32. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 1999;141:385-394.
33. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 2013;18:993-1002.